Top Markets
#1 Islamic Coin Islamic Coin +151.53%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#3 Palladium Network Palladium Network +14.30%
#4 clBTC clBTC +12.18%
#5 Not in Employment, Education, or Training Not in Employment, Education, or Training +9.58%
#6 OpenEden OpenEden +9.30%
#7 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.83%
#8 Mantle Staked Ether Mantle Staked Ether +8.33%
#9 MarsCoin MarsCoin +8.26%
#10 Mantle Restaked ETH Mantle Restaked ETH +8.10%
Coin of the day
Islamic Coin Islamic Coin
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
Infinity Pharmaceuticals, Inc. Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

INFI
Classement en actions #40134
Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge,... Infinity Pharmaceuticals, Inc., established in 1995 and based in Cambridge, Massachusetts, operates as a biopharmaceutical firm dedicated to creating innovative therapies for individuals battling cancer. A central component of its pipeline is IPI-549, an experimental immuno-oncology drug taken orally. This candidate, currently in clinical development, functions by blocking the phosphoinositide-3-kinase-gamma enzyme. IPI-549 is undergoing Phase 2 trials for metastatic triple negative breast cancer and urothelial cancer, and Phase 1/1b trials for various solid tumors. The company maintains several strategic partnerships: with Intellikine, Inc. for the discovery, development, and commercialization of PI3K delta and/or gamma isoform-targeting pharmaceuticals; with Verastem, Inc. for the research, development, commercialization, and production of duvelisib and related compounds; and with PellePharm, Inc. to advance and commercialize its hedgehog inhibitor program, IPI-926, which is also a clinical-stage investigational drug. Furthermore, Infinity Pharmaceuticals holds collaborative agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company.
Prix de l'action
$0.0039
Dernière synchronisation: 2023-10-27
Capitalisation boursière
$235.97K
Changement (1 jour)
-13.33%
Changement (1 an)
0.00%
Pays
US
Échange Infinity Pharmaceuticals, Inc. (INFI)

Catégorie

Healthcare
Revenus pour Infinity Pharmaceuticals, Inc. (INFI)
Revenus en Aug 2026 TTM : 0
Selon les derniers rapports financiers de Infinity Pharmaceuticals, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de 0. En 2026, l'entreprise a réalisé un chiffre d'affaires de 0 égal à le chiffre d'affaires de l'année 2026, qui était de 0. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Infinity Pharmaceuticals, Inc. de 2026 à 2026
Revenus à la fin de chaque année
Année Revenus Changez
Pas assez de données pour les dates fournies.
Revenus d’entreprises similaires ou concurrentes
Entreprise Revenus Différence de revenus Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE